摘要
Prostate cancer remains a leading cause of death in men in the United States.1＇2 Treatment for advanced disease almost always includes androgen deprivation therapy （ADT）3 largely because the androgen receptor （AR） is expressed at high levels at many stages of disease progression. The clinical res- ponse to ADT typically includes a reduc- tion in overall tumor burden and reduced serum levels of the AR target, prostate- specific antigen （PSA）.4
Prostate cancer remains a leading cause of death in men in the United States.1＇2 Treatment for advanced disease almost always includes androgen deprivation therapy （ADT）3 largely because the androgen receptor （AR） is expressed at high levels at many stages of disease progression. The clinical res- ponse to ADT typically includes a reduc- tion in overall tumor burden and reduced serum levels of the AR target, prostate- specific antigen （PSA）.4
